<DOC>
	<DOCNO>NCT02170402</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety pharmacokinetics ADVATE treatment prevention bleed episode ( BEs )</brief_summary>
	<brief_title>China ADVATE PTP Study</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Main Ethnic Chinese age document diagnosis severe moderately severe hemophilia A ( congenital FVIII deficiency : baseline Factor VIII ( FVIII ) ≤ 2 % ) document verified &gt; 50 exposure day ( EDs ) FVIII ( recombinant plasma derive ) receive ondemand treatment FVIII time enrolment study negative history inhibitor development HIV negative HIV positive stable disease CD4+ count ≥ 200 cell per mm^3 negative Hepatitis C virus ( HCV ) ; Or participant HCV positive chronic stable hepatitis assess investigator Main prior history hypersensitivity anaphylaxis associate receipt FVIII diagnose bleed disorder ( ) hemophilia A , include limit thrombocytopenia ( platelet count &lt; 100000 /mL ) expose investigational product ( IP ) within 30 day prior screen visit schedule participate another clinical study involve IP investigational device participation study plan , likely surgery study period endstage renal failure evidence severe uncontrolled systemic disease judge investigator active hepatic disease ( alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level &gt; 5 time upper limit normal ) clinical laboratory evidence severe liver impairment include ( limited ) recent &amp; persistent international normalize ratio ( INR ) &gt; 1.4 , and/or presence splenomegaly and/or significant spider angioma physical exam , and/or history esophageal hemorrhage document esophageal varix family member investigator site staff</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>